Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn?

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089

Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802

Myeloid-derived-suppressor cells as regulators of the immune system

Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449

Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer

Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400

Exosomes: composition, biogenesis and function

Théry, C., Zitvogel, L., & Amigorena, S. (2002) · Nature reviews. Immunology · doi:10.1038/nri855 · Cited by 5,355

The immune contexture in human tumours: impact on clinical outcome

Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981

Neoantigens in cancer immunotherapy

Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

Rittmeyer, A., Barlési, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Cobo, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32517-x · Cited by 4,718

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Zhou, C., Wu, Y.-L., Chen, G., Feng, J., Liu, X.-Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70184-x · Cited by 4,081

Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden

Chalmers, Z. R., Connelly, C. F., Fabrizio, D., Gay, L., Ali, S. M., Ennis, R., Schrock, A., Campbell, B., Shlien, A., Chmielecki, J., et al. (2017) · Genome Medicine · doi:10.1186/s13073-017-0424-2 · Cited by 3,519

Tumour-educated macrophages promote tumour progression and metastasis

Pollard, J. W. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1256 · Cited by 3,413

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations

Sequist, L. V., Yang, J. C.-H., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., Geater, S. L., Orlov, S., Tsai, C.-M., Boyer, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.2806 · Cited by 3,228

Targeting the IL-6/JAK/STAT3 signalling axis in cancer

Johnson, D. E., O'Keefe, R. A., & Grandis, J. R. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.8 · Cited by 3,110

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., Park, K., Smith, D., Artal-Cortes, A., Lewanski, C., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00587-0 · Cited by 2,756

First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

Carbone, D. P., Reck, M., Paz-Ares, L., Creelan, B., Horn, L., Steins, M., Felip, E., van den Heuvel, M. M., Ciuleanu, T.-E., Badin, F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613493 · Cited by 2,503

Ido expression by dendritic cells: tolerance and tryptophan catabolism

Mellor, A. L., & Munn, D. H. (2004) · Nature Reviews Immunology · doi:10.1038/nri1457 · Cited by 2,341

The immune contexture in cancer prognosis and treatment

Fridman, W. H., Zitvogel, L., Sautès–Fridman, C., & Kroemer, G. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.101 · Cited by 2,263

PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity

Gordon, S. R., Maute, R. L., Dulken, B. W., Hutter, G., George, B. M., McCracken, M. N., Gupta, R., Tsai, J. M., Sinha, R., Corey, D., et al. (2017) · Nature · doi:10.1038/nature22396 · Cited by 2,247

PD-L1 regulates the development, maintenance, and function of induced regulatory T cells

Francisco, L. M., Salinas, V. H., Brown, K. E., Vanguri, V. K., Freeman, G. J., Kuchroo, V. K., & Sharpe, A. H. (2009) · The Journal of Experimental Medicine · doi:10.1084/jem.20090847 · Cited by 2,072

The tumor microenvironment at a glance

Balkwill, F. R., Capasso, M., & Hagemann, T. (2012) · Journal of Cell Science · doi:10.1242/jcs.116392 · Cited by 1,857

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma

Skoulidis, F., Goldberg, M. E., Greenawalt, D. M., Hellmann, M. D., Awad, M. M., Gainor, J. F., Schrock, A. B., Hartmaier, R. J., Trabucco, S. E., Gay, L., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0099 · Cited by 1,641

A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)

Shi, Y., Au, J. S. K., Thongprasert, S., Srinivasan, S., Tsai, C., Khoa, M. T., Heeroma, K., Itoh, Y., Cornelio, G. H., & Yang, P. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000033 · Cited by 1,575

Classifying Cancers Based on T-cell Infiltration and PD-L1

Teng, M. W. L., Ngiow, S. F., Ribas, A., & Smyth, M. J. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0255 · Cited by 1,436

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

Mazières, J., Drilon, A. E. D. C., Lusque, A., Mhanna, L., Cortot, A. B., Mezquita, L., Thai, A. A., Mascaux, C., Couraud, S., Veillon, R., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz167 · Cited by 1,377

Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway

Boussiotis, V. A. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1514296 · Cited by 1,372

Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates

Simoni, Y., Becht, E., Fehlings, M., Loh, C. Y., Koo, S.-L., Teng, K. W. W., Yeong, J. P. S., Nahar, R., Zhang, T., Kared, H., et al. (2018) · Nature · doi:10.1038/s41586-018-0130-2 · Cited by 1,370

EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis

Gainor, J. F., Shaw, A. T., Sequist, L. V. D., Fu, X., Azzoli, C. G., Piotrowska, Z., Huynh, T. G., Zhao, L., Fulton, L. E., Schultz, K. R., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-3101 · Cited by 1,268

VEGF targets the tumour cell

Goel, H. L., & Mercurio, A. M. (2013) · Nature reviews. Cancer · doi:10.1038/nrc3627 · Cited by 1,258

Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors

Akbay, E. A., Koyama, S., Carretero, J., Altabef, A. B., Tchaicha, J. H., Christensen, C. L., Mikse, O. R., Cherniack, A. D., Beauchamp, E. M., Pugh, T. J., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0310 · Cited by 1,250

NK cells and cancer: you can teach innate cells new tricks

Morvan, M. G., & Lanier, L. L. (2015) · Nature reviews. Cancer · doi:10.1038/nrc.2015.5 · Cited by 1,190

IL-10 Family Cytokines IL-10 and IL-22: from Basic Science to Clinical Translation

Ouyang, W., & O’Garra, A. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.020 · Cited by 1,141

Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity

Li, C., Lim, S., Xia, W., Lee, H., Chan, L.-C., Kuo, C., Khoo, K., Chang, S.-S., Cha, J., Kim, T., et al. (2016) · Nature Communications · doi:10.1038/ncomms12632 · Cited by 1,136

PD-1 + regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer

Kamada, T., Togashi, Y., Tay, C., Ha, D., Sasaki, A., Nakamura, Y., Sato, E., Fukuoka, S., Tada, Y., Tanaka, A., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1822001116 · Cited by 1,035

Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial

Reck, M., Mok, T. S. K., Nishio, M., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez‐Abreu, D., Moro‐Sibilot, D., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30084-0 · Cited by 1,001

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study

Hellmann, M. D., Rizvi, N. A., Goldman, J. W., Gettinger, S. N., Borghaei, H., Brahmer, J. R., Ready, N. E., Gerber, D. E., Chow, L. Q., Juergens, R. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30624-6 · Cited by 962

Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

Dong, Z.-Y., Zhong, W.-Z., Zhang, X.-C., Su, J., Xie, Z., Liu, S.-Y., Tu, H.-Y., Chen, H.-J., Sun, Y.-L., Zhou, Q., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2554 · Cited by 959

Co-occurring Genomic Alterations Define Major Subsets of KRAS -Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities

Skoulidis, F., Byers, L. A., Diao, L., Papadimitrakopoulou, V. A., Tong, P., Izzo, J., Behrens, C., Kadara, H., Parra, E. R., Canales, J. R., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1236 · Cited by 936

Regulation of human NK-cell cytokine and chemokine production by target cell recognition

Fauriat, C., Long, E. O., Ljunggren, H., & Bryceson, Y. T. (2009) · Blood · doi:10.1182/blood-2009-08-238469 · Cited by 894

Dendritic-Cell-Based Therapeutic Cancer Vaccines

Palucka, K., & Banchereau, J. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.004 · Cited by 869

Targeting immunosuppressive adenosine in cancer

Vijayan, D., Young, A., Teng, M. W. L., & Smyth, M. J. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2017.86 · Cited by 867

Checkpoint inhibitors in metastatic EGFR-mutated non–small cell lung cancer-a meta-analysis

Lee, C. K., Man, J., Lord, S., Links, M., Gebski, V., Mok, T., & Yang, J. C.-H. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.10.007 · Cited by 839

Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate

(2017) · doi:10.1158/1078-0432.ccr-16-3133 · Cited by 831

The “cancer immunogram”

Blank, C. U., Haanen, J. B., Ribas, A., & Schumacher, T. N. (2016) · Science · doi:10.1126/science.aaf2834 · Cited by 748

Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 Study

Gettinger, S. N., Horn, L., Jackman, D. M., Spigel, D. R., Antonia, S. J., Hellmann, M. D., Powderly, J. D., Heist, R. S., Sequist, L. V. D., Smith, D. C., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.0412 · Cited by 745

A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer

Ott, P. A., Hu-Lieskovan, S., Chmielowski, B., Govindan, R., Naing, A., Bhardwaj, N., Margolin, K., Awad, M. M., Hellmann, M. D., Lin, J. J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.053 · Cited by 738

The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer

Naugler, W. E., & Karin, M. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.12.007 · Cited by 730

Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy

Ferrara, R., Mezquita, L., Texier, M., Lahmar, J., Audigier-Valette, C., Tessonnier, L., Mazieres, J., Zalcman, G., Brosseau, S., Le Moulec, S., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.3676 · Cited by 720

Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR

Al-Nedawi, K. N. I., Meehan, B., Kerbel, R. S., ALLISON, A. C., & Rak, J. W. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804543106 · Cited by 691

Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation

Chen, N., Fang, W., Zhan, J., Hong, S., Tang, Y., Kang, S., Zhang, Y., He, X., Zhou, T., Qin, T., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000500 · Cited by 681

Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer

Azuma, K., Ota, K., Kawahara, A., Hattori, S., Iwama, E., Harada, T., Matsumoto, K., Takayama, K., Takamori, S., Kage, M., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu242 · Cited by 649

Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.

Ciardiello, F., Caputo, R., Bianco, R., Damiano, V., Fontanini, G., Cuccato, S., Placido, S. D., Bianco, A. R., & Tortora, G. (2001) · PubMed · Cited by 643

Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non–Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis

Lee, C. K., Man, J., Lord, S., Cooper, W., Links, M., Gebski, V., Herbst, R. S., Gralla, R. J., Mok, T., & Yang, J. C.-H. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.4427 · Cited by 598

A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC

Lisberg, A., Cummings, A., Goldman, J. W., Bornazyan, K., Reese, N., Wang, T., Coluzzi, P., Ledezma, B., Mendenhall, M., Hunt, J., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.03.035 · Cited by 580

Exosome-delivered EGFR regulates liver microenvironment to promote gastric cancer liver metastasis

Zhang, H., Deng, T., Liu, R., Bai, M., Zhou, L., Wang, X., Li, S., Wang, X., Yang, H., Li, J., et al. (2017) · Nature Communications · doi:10.1038/ncomms15016 · Cited by 568

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

Garassino, M. C., Cho, B.-C., Kim, J.-H., Mazières, J., Vansteenkiste, J., Lena, H., Corral Jaime, J., Gray, J. E., Powderly, J., Chouaid, C., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30144-x · Cited by 568

IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation

Park, S.-J., Nakagawa, T., Kitamura, H., Atsumi, T., Kamon, H., Sawa, S.-I., Kamimura, D., Ueda, N., Iwakura, Y., Ishihara, K., et al. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.6.3844 · Cited by 519

Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

Gettinger, S., Rizvi, N. A., Chow, L. Q., Borghaei, H., Brahmer, J., Ready, N., Gerber, D. E., Shepherd, F. A., Antonia, S., Goldman, J. W., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.9929 · Cited by 501

Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner

Holmgaard, R., Zamarin, D., Li, Y., Gasmi, B., Munn, D. H., Allison, J. P., Merghoub, T., & Wolchok, J. D. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.08.077 · Cited by 496

Serine phosphorylation and maximal activation of STAT3 during CNTF signaling is mediated by the rapamycin target mTOR

Yokogami, K., Wakisaka, S., Avruch, J., & Reeves, S. A. (2000) · Current Biology · doi:10.1016/s0960-9822(99)00268-7 · Cited by 474

Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients

Sanmamed, M. F., Perez‐Gracia, J. L., Schalper, K. A., Fusco, J. P., González, Á., Rodriguez-Ruiz, M. E., Oñate, C., Perez, G., Alfaro, C., Martín‐Algarra, S., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx190 · Cited by 470

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor–Resistant Disease

Ohashi, K., Maruvka, Y. E., Michor, F., & Pao, W. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.3912 · Cited by 467

Nivolumab in Combination With Platinum‐Based Doublet Chemotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

Rizvi, N. A., Hellmann, M. D., Brahmer, J. R., Juergens, R. A., Borghaei, H., Gettinger, S. N., Chow, L. Q. M., Gerber, D. E., Laurie, S. A., Goldman, J. W., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.9861 · Cited by 450

EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer

Dong, Z.-Y., Zhang, J.-T., Liu, S.-Y., Su, J., Zhang, C., Xie, Z., Zhou, Q., Tu, H.-Y., Xu, C.-R., Yan, L.-X., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1356145 · Cited by 440

TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer

Oxnard, G. R., Yang, J. C.-H., Yu, H., Kim, S.-W., Saka, H., Horn, L., Goto, K., Ohe, Y., Mann, H., Thress, K. S., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.01.013 · Cited by 438

Amphiregulin Enhances Regulatory T Cell-Suppressive Function via the Epidermal Growth Factor Receptor

Zaiss, D. M. W., van Loosdregt, J., Gorlani, A., Bekker, C. P. J., Gröne, A., Sibilia, M. C., Henegouwen, P. M. P. V. B. E., Roovers, R. C., Coffer, P. J., & Sijts, A. J. A. M. (2013) · Immunity · doi:10.1016/j.immuni.2012.09.023 · Cited by 433

Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib

Schoenfeld, A. J., Arbour, K. C., Rizvi, H., Iqbal, A. N., Gadgeel, S. M., Girshman, J., Kris, M. G., Riely, G. J., Yu, H. A., & Hellmann, M. D. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz077 · Cited by 406

Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1–Selected Advanced Non–Small-Cell Lung Cancer (BIRCH)

Peters, S., Gettinger, S. N., Johnson, M. L., Janne, P. A., Garassino, M. C., Christoph, D. C., Toh, C., Rizvi, N. A., Chaft, J. E., Carcereny, E., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.9476 · Cited by 401

Tumor neoantigens: from basic research to clinical applications

Jiang, T., Shi, T., Zhang, H., Hu, J., Song, Y., Wei, J., Ren, S., & Zhou, C. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0787-5 · Cited by 401

CD39 Expression Identifies Terminally Exhausted CD8+ T Cells

Gupta, P., Godec, J., Wolski, D., Adland, E., Yates, K. B., Pauken, K. E., Cosgrove, C., Ledderose, C., JUNGER, W. G., Robson, S. C., et al. (2015) · PLoS Pathogens · doi:10.1371/journal.ppat.1005177 · Cited by 384

Hyperprogressive disease: recognizing a novel pattern to improve patient management

Champiat, S., Ferrara, R., Massard, C., Besse, B., Marabelle, A., Soria, J., & Ferté, C. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0111-2 · Cited by 366

The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer

Zhang, N., Zeng, Y., Du, W., Zhu, J., Shen, D., Liu, Z., & Huang, J.-A. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3632 · Cited by 362

Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC

Le, X., Nilsson, M. B., Goldman, J. W., Reck, M., Nakagawa, K., Kato, T., Ares, L. P., Frimodt‐Moller, B., Wolff, K., Visseren‐Grul, C., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.10.006 · Cited by 357

Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non–Small-Cell Lung Cancer

Brambilla, E. M., Teuff, G. L., Marguet, S., Lantuéjoul, S., Dunant, A., Graziano, S. L., Pirker, R., Douillard, J.-Y., Chevalier, T. L., Filipits, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.0970 · Cited by 351

Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy

Chowell, D., Krishna, C., Pierini, F., Makarov, V., Rizvi, N. A., Kuo, F., Morris, L. G. T., Riaz, N., Lenz, T. L., & Chan, T. A.-T. (2019) · Nature Medicine · doi:10.1038/s41591-019-0639-4 · Cited by 324

Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR -Mutated Non–Small Cell Lung Cancer

Castellanos, E. H., Feld, E., & Horn, L. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.12.014 · Cited by 322

Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas

Schoenfeld, A. J., Rizvi, H., Bandlamudi, C., Sauter, J. L., Travis, W. D., Rekhtman, N., Plodkowski, A. J., Pérez-Johnston, R., Sawan, P., Beras, A., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.01.065 · Cited by 322

Targeting Cancer-Derived Adenosine:New Therapeutic Approaches

Young, A., Mittal, D., Stagg, J., & Smyth, M. J. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0341 · Cited by 318

EGFR–TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients With Non–Small Cell Lung Cancer

Oshima, Y., Tanimoto, T., Yuji, K., & Tojo, A. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.4526 · Cited by 313

Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment

Haratani, K., Hayashi, H., Tanaka, T., Kaneda, H., Togashi, Y., Sakai, K., Hayashi, K., Tomida, S., Chiba, Y., Yonesaka, K., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx183 · Cited by 300

Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR -mutated non–small cell lung cancer

Sugiyama, E., Togashi, Y., Takeuchi, Y., Shinya, S., Tada, Y., Kataoka, K., Tane, K., Sato, E., Ishii, G., Goto, K., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.aav3937 · Cited by 295

Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by TIM-3 Upregulation and Regulatory T-Cell Infiltration

Oweida, A., Hararah, M. K., Phan, A. V., Binder, D. C., Bhatia, S., Lennon, S., Bukkapatnam, S., Court, B. V., Uyanga, N., Darragh, L. B., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1038 · Cited by 283

Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations

Lin, A., Wei, T., Meng, H., Luo, P., & Zhang, J. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1062-7 · Cited by 266

PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8+ T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients

Naing, A., Infante, J. R., Papadopoulos, K. P., Chan, I. H., Shen, C., Ratti, N. P., Rojo, B., Autio, K. A., Wong, D. J. L., Patel, M. R., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.10.007 · Cited by 258

Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in EGFR Mutation–Positive Non–Small Cell Lung Cancer

Isomoto, K., Haratani, K., Hayashi, H., Shimizu, S., Tomida, S., Niwa, T., Yokoyama, T., Fukuda, Y., Chiba, Y., Kato, R., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2027 · Cited by 255

Single-cell RNA sequencing reveals heterogeneous tumor and immune cell populations in early-stage lung adenocarcinomas harboring EGFR mutations

He, D., Wang, D., Lü, P., Yang, N., Xue, Z., Zhu, X., Zhang, P., & Fan, G. (2020) · Oncogene · doi:10.1038/s41388-020-01528-0 · Cited by 249

EGFR and NF-κB: partners in cancer

Shostak, K., & Chariot, A. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.04.001 · Cited by 222

Phenotype, development, and biological function of myeloid-derived suppressor cells

Zhao, Y., Wu, T., Shao, S., Shi, B., & Zhao, Y. X. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1004983 · Cited by 220

Comprehensive T cell repertoire characterization of non-small cell lung cancer

Reuben, A., Zhang, J., Chiou, S.-H., Gittelman, R. M., Li, J., Lee, W.-C., Fujimoto, J., Behrens, C., Liu, X., Wang, F., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14273-0 · Cited by 220

Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC)

Hsu, P., Jablons, D. M., Yang, C., & You, L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20153821 · Cited by 215

Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M–Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report

Yang, J. C.-H., Shepherd, F. A., Kim, D.-W., Lee, G.-W., Lee, J. S., Chang, G.-C., Lee, S. S., Wei, Y.-F., Lee, Y. G., Laus, G., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.02.001 · Cited by 210

Higher levels of GATA3 predict better survival in women with breast cancer

Yoon, N. K., Maresh, E. L., Shen, D., Elshimali, Y., Apple, S. K., Horvath, S., Mah, V. H., Bose, S., Chia, D., Chang, H. R., et al. (2010) · Human Pathology · doi:10.1016/j.humpath.2010.06.010 · Cited by 208

A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers

Gettinger, S. N., Choi, J., Mani, N. L., Sanmamed, M. F., Datar, I. J., Sowell, R., Du, V. Y., Kaftan, E. J., Goldberg, S. B., Dong, W., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05032-8 · Cited by 188

Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation

Yang, J. C., Gadgeel, S. M., Sequist, L. V. D., Wu, C.-L., Papadimitrakopoulou, V. A., Su, W., Fiore, J., Saraf, S., Raftopoulos, H., & Patnaik, A. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.11.028 · Cited by 185

Clinical Significance of PD-L1 Protein Expression in Surgically Resected Primary Lung Adenocarcinoma

Takada, K., Okamoto, T., Shoji, F., Shimokawa, M., Akamine, T., Takamori, S., Katsura, M., Suzuki, Y., Fujishita, T., Toyokawa, G., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.06.006 · Cited by 183

TGF ‐β transactivates EGFR and facilitates breast cancer migration and invasion through canonical Smad3 and ERK /Sp1 signaling pathways

Zhao, Y., Ma, J., Fan, Y., Wang, Z., Tian, R., Ji, W., Zhang, F., & Niu, R. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12162 · Cited by 175

A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non–Small Cell Lung Cancer Patients

Rodríguez, P. C., Popa, X., Martínez, O., Mendoza, S., Santiesteban, E. R., Crespo, T., Amador, R. M., Fleytas, R., Acosta, S. C., Otero, Y., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0855 · Cited by 173

Epidermal Growth Factor Receptor Inhibition Augments the Expression of MHC Class I and II Genes

Pollack, B. P., Sapkota, B., & Cartee, T. V. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3283 · Cited by 169

EGFR‐targeted therapy alters the tumor microenvironment in EGFR‐driven lung tumors: Implications for combination therapies

Jia, Y., Li, X., Jiang, T., Zhao, S., Zhao, C., Zhang, L., Liu, X., Shi, J., Qiao, M., Luo, J., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32191 · Cited by 164

Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non–small-cell lung cancer: The global, multicenter EXPRESS study

Dietel, M., Савелов, Н. А., Salanova, R., Micke, P., Bigras, G., Hida, T., López, J. R. A., Skov, B. G., Hutarew, G., Sua, L. F., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.06.012 · Cited by 163

Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions

Soo, R. A., Lim, S. M., Syn, N. L. X., Teng, R. S. Y., Soong, R., Mok, T. S. K., & Cho, B. C. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.11.009 · Cited by 156

Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against Melanoma

Hogan, S. A., Courtier, A., Cheng, P. F., Jaberg-Bentele, N. F., Goldinger, S. M., Manuel, M., Perez, S., Plantier, N., Mouret, J.-F., Nguyen‐Kim, T. D. L., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0136 · Cited by 155

Epidermal Growth Factor Receptor-Containing Exosomes Induce Tumor-Specific Regulatory T Cells

Huang, S., Li, Y., Zhang, J., Rong, J., & Ye, S. (2013) · Cancer Investigation · doi:10.3109/07357907.2013.789905 · Cited by 154

EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-κB

Lin, K., Cheng, J., Yang, T., Li, Y., & Zhu, B. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.05.030 · Cited by 152

EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice

Gahr, S., Stoehr, R., Geissinger, E., Ficker, J. H., Brueckl, W. M., Gschwendtner, A., Gattenloehner, S., Fuchs, F. S., Schulz, C. K. J., Rieker, R. J., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.511 · Cited by 150

M2 macrophage infiltration into tumor islets leads to poor prognosis in non-small-cell lung cancer

Cao, L., Che, X., Qiu, X.-S., Li, Z., Yang, B., Wang, S., Hou, K., Fan, Y., Qu, X., & Liu, Y. (2019) · Cancer Management and Research · doi:10.2147/cmar.s199832 · Cited by 146

Comprehensive evaluation of NT5E/CD73 expression and its prognostic significance in distinct types of cancers

Jiang, T., Xu, X., Qiao, M., Li, X., Zhao, C., Zhou, F., Gao, G., Wu, F., Chen, X., Su, C., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-4073-7 · Cited by 141

Targeting γδ T Lymphocytes for Cancer Immunotherapy: From Novel Mechanistic Insight to Clinical Application

Gomes, A. Q., Martins, D., & Silva‐Santos, B. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-3236 · Cited by 134

Cytokine and Chemokine Signals of T‐Cell Exclusion in Tumors

Zhang, Y., Guan, X.-Y., & Jiang, P. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.594609 · Cited by 133

Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target

Le, X., Negrao, M. V., Reuben, A., Federico, L., Diao, L., McGrail, D. J., Nilsson, M. B., Robichaux, J. P., Guijarro, I., Patel, S. A., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.12.010 · Cited by 128

PD-1/PD-L1 expression in non-small-cell lung cancer and its correlation with EGFR/KRAS mutations

Ji, M., Liu, Y., Li, Q., Li, X., Ning, Z., Zhao, W., Shi, H., Jiang, J., & Wu, C. (2016) · Cancer Biology & Therapy · doi:10.1080/15384047.2016.1156256 · Cited by 126

Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial

Naing, A., Wong, D. J. L., Infante, J. R., Korn, W. M., Aljumaily, R. M., Papadopoulos, K. P., Autio, K. A., Pant, S., Bauer, T. M., Drakaki, A., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30514-5 · Cited by 124

Harnessing γδ T cells in anticancer immunotherapy

Hannani, D., Ma, Y., Yamazaki, T., Déchanet‐Merville, J., Kroemer, G., & Zitvogel, L. (2012) · Trends in Immunology · doi:10.1016/j.it.2012.01.006 · Cited by 117

PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non–Small Cell Lung Cancer

Negrao, M. V., Lam, V. K. L., Reuben, A., Rubin, M. L., Landry, L. L., Roarty, E. B., Rinsurongkawong, W., Lewis, J., Roth, J. A., Swisher, S. G., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.02.008 · Cited by 115

Potential mechanism of interleukin‐8 production from lung cancer cells: An involvement of EGF–EGFR–PI3K–Akt–Erk pathway

Zhang, Y., Wang, L., Zhang, M., Jin, M., Bai, C., & Wang, X. (2011) · Journal of Cellular Physiology · doi:10.1002/jcp.22722 · Cited by 114

Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations

Toki, M. I., Mani, N. L., Smithy, J. W., Liu, Y., Altan, M., Wasserman, B. E., Tuktamyshov, R., Schalper, K. A., Syrigos, K. N., & Rimm, D. L. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.09.012 · Cited by 114

Genomic landscape and its correlations with tumor mutational burden, PD-L1 expression, and immune cells infiltration in Chinese lung squamous cell carcinoma

Jiang, T., Shi, J., Dong, Z., Hou, L., Zhao, C., Li, X., Mao, B., Zhu, W., Guo, X., Zhang, H., et al. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0762-1 · Cited by 108

Oncogenic KRAS‐induced interleukin‐8 overexpression promotes cell growth and migration and contributes to aggressive phenotypes of non‐small cell lung cancer

Sunaga, N., Imai, H., Shimizu, K., Shames, D. S., Kakegawa, S., Girard, L., Sato, M., Kaira, K., Ishizuka, T., Gazdar, A. F., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.26164 · Cited by 103

Tumor‐associated macrophages correlate with response to epidermal growth factor receptor‐tyrosine kinase inhibitors in advanced non‐small cell lung cancer

Chung, F., Lee, K., Wang, C., Heh, C., Chan, Y., Chen, H., Kuo, C.-H. S., Feng, P., Lin, T., Wang, C., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.27403 · Cited by 101

TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer

Gong, K., Guo, G., Gerber, D. E., Gao, B., Peyton, M., Huang, C., Minna, J. D., Hatanpaa, K. J., Kernstine, K., Cai, L., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96148 · Cited by 98

Clinicopathological and genomic correlates of programmed cell death ligand 1 (PD-L1) expression in nonsquamous non-small-cell lung cancer

Lamberti, G., Spurr, L. F., Li, Y. Y., Ricciuti, B., Recondo, G., Umeton, R., Nishino, M., Sholl, L. M., Meyerson, M. M., Cherniack, A. D., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.02.017 · Cited by 98

Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non–Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor

Kim, Y., Kim, C. H., Lee, H. Y., Lee, S., Kim, H. S., Lee, S., Cha, H., Hong, S., Kim, K., Seo, S. W., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.05.033 · Cited by 97

MDSC subtypes and CD39 expression on CD8 + T cells predict the efficacy of anti‐PD‐1 immunotherapy in patients with advanced NSCLC

Koh, J., Kim, Y., Lee, K. Y., Hur, J. Y., Kim, M. S., Kim, B., Cho, H. J., Lee, Y. C., Bae, Y. H., Ku, B. M., et al. (2020) · European Journal of Immunology · doi:10.1002/eji.202048534 · Cited by 95

Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1α in non-small cell lung cancer cells

Xu, L., Nilsson, M. B., Saintigny, P., Cascone, T., Herynk, M. H., Du, Z., Nikolinakos, P. G., Yang, Y., Prudkin, L., Liu, D., et al. (2010) · Oncogene · doi:10.1038/onc.2010.16 · Cited by 93

Amphiregulin expression in human mast cells and its effect on the primary human lung fibroblasts

Wang, S., Oh, C. K., Cho, S., Hu, G., Martin, R. E., Demissie-Sanders, S., Li, K., Moyle, M., & Yao, Z. (2005) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2004.11.037 · Cited by 90

Clinical Development and Perspectives of CIMAvax EGF, Cuban Vaccine for Non-small-cell Lung Cancer Therapy

Rodríguez, P. C., Rodríguez, G., González, G., & Lage, A. (2010) · MEDICC Review · doi:10.37757/mr2010.v12.n1.4 · Cited by 90

CIMAvax-EGF: A New Therapeutic Vaccine for Advanced Non-Small Cell Lung Cancer Patients

Saavedra, D., & Crombet, T. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00269 · Cited by 90

NK cell-based therapeutics for lung cancer

Pockley, A. G., Vaupel, P. W., & Multhoff, G. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1688298 · Cited by 89

PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy

Chen, K., Cheng, G., Zhang, F., Zhu, G., Xu, Y., Yu, X., Huang, Z., & Fan, Y. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.02.010 · Cited by 89

A high-throughput immune-oncology screen identifies EGFR inhibitors as potent enhancers of antigen-specific cytotoxic T-lymphocyte tumor cell killing

Lizotte, P. H., Hong, R.-L., Luster, T. A., Cavanaugh, M. E., Taus, L. J., Wang, S., Dhaneshwar, A., Mayman, N., Yang, A., Kulkarni, M., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0193 · Cited by 88

Italian Nivolumab Expanded Access Program in Nonsquamous Non–Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients

Garassino, M. C., Gelibter, A. J., Grossi, F., Chiari, R., Parra, H. J. S., Cascinu, S., Cognetti, F., Turci, D., Blasi, L., Bengala, C., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.04.025 · Cited by 85

HIF, hypoxia and the role of angiogenesis in non-small cell lung cancer

Jackson, A. L., Zhou, B. R., & Kim, W. Y. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2010.511617 · Cited by 82

Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non–small-cell lung cancer: KEYNOTE-021 cohorts D and H

Gubens, M. A., Sequist, L. V. D., Stevenson, J. P., Powell, S. F., Villaruz, L. C., Gadgeel, S. M., Langer, C. J., Patnaik, A., Borghaei, H., Jalal, S. I., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.12.015 · Cited by 82

Dendritic cell-based therapeutic cancer vaccines: past, present and future

Ahmed, M. S., & Bae, Y. (2014) · Clinical and Experimental Vaccine Research · doi:10.7774/cevr.2014.3.2.113 · Cited by 73

Predictive biomarkers for hyper-progression (HP) in response to immune checkpoint inhibitors (ICI) – analysis of somatic alterations (SAs)

Singavi, A. K., Menon, S., Kilari, D., Alqwasmi, A., Ritch, P. S., Thomas, J. P., Martin, A. L., Oxencis, C. J., Ali, S. S., & George, B. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx376.006 · Cited by 73

Immune regulation and cytotoxic T cell activation of IL-10 agonists – Preclinical and clinical experience

Oft, M. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.101325 · Cited by 71

EGFR E746-A750 deletion in lung cancer represses antitumor immunity through the exosome-mediated inhibition of dendritic cells

Yu, S., Sha, H., Qin, X., Chen, Y., Li, X., Shi, M., & Feng, J. (2020) · Oncogene · doi:10.1038/s41388-020-1182-y · Cited by 71

Intratumoral Immune Cell Densities Are Associated with Lung Adenocarcinoma Gene Alterations

Mansuet‐Lupo, A., Alifano, M., Pécuchet, N., Biton, J., Becht, É., Goc, J., Germain, C., Ouakrim, H., Régnard, J., Cremer, I., et al. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201510-2031oc · Cited by 67

Tumour Microenvironment and Immune Evasion in EGFR Addicted NSCLC: Hurdles and Possibilities

Santaniello, A., Napolitano, F., Servetto, A., Placido, P. D., Silvestris, N., Bianco, C., Formisano, L., & Bianco, R. (2019) · Cancers · doi:10.3390/cancers11101419 · Cited by 61

Characterization of T cell repertoire of blood, tumor, and ascites in ovarian cancer patients using next generation sequencing

Jang, M., Yew, P., Hasegawa, K., Ikeda, Y., Fujiwara, K., Fleming, G. F., Nakamura, Y., & Park, J.-H. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1030561 · Cited by 60

Erlotinib inhibits T-cell-mediated immune response via down-regulation of the c-Raf/ERK cascade and Akt signaling pathway

Luo, Q., Gu, Y., Zheng, W., Wu, X., Gong, F., Gu, L., Sun, Y., & Xu, Q. (2011) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2010.12.011 · Cited by 60

Mutational activation of the epidermal growth factor receptor down‐regulates major histocompatibility complex class I expression via the extracellular signal‐regulated kinase in non–small cell lung cancer

Watanabe, S., Hayashi, H., Haratani, K., Shimizu, S., Tanizaki, J., Sakai, K., Kawakami, H., Yonesaka, K., Tsurutani, J., Togashi, Y., et al. (2018) · Cancer Science · doi:10.1111/cas.13860 · Cited by 57

Prognostic value of PD ‐L1 expression in combination with CD 8 + TIL s density in patients with surgically resected non‐small cell lung cancer

Yang, H. J., Shi, J., Lin, D., Li, X., Zhao, C., Wang, Q., Zhang, L., Jiang, T., Zhao, S., Liu, X., et al. (2017) · Cancer Medicine · doi:10.1002/cam4.1243 · Cited by 50

PD‐L1 expression in ROS1‐rearranged non‐small cell lung cancer: A study using simultaneous genotypic screening of EGFR, ALK, and ROS1

Lee, J. M., Park, C. K., Yoon, H. K., Jo, Y., Woo, I. S., Kim, H. R., Kim, S. Y., & Kim, T. J. (2018) · Thoracic Cancer · doi:10.1111/1759-7714.12917 · Cited by 47

Increased CD73 and reduced IFNG signature expression in relation to response rates to anti-PD-1(L1) therapies in EGFR-mutant NSCLC.

Streicher, K. L., Higgs, B. W., Wu, S., Coffman, K. T., Damera, G., Durham, N., Greenlees, L. M., Lazdun, Y., Li, C., Cooper, Z. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.11505 · Cited by 45

441O Preliminary safety and clinical activity of erlotinib plus atezolizumab from a Phase Ib study in advanced NSCLC

Ma, B. B. Y., Rudin, C. M., Cervantes, A. M. R., Dowlati, A., Costa, D. B., Schmid, P., Heist, R. S., Villaflor, V. M., Sarkar, I., Huseni, M. A., et al. (2016) · Annals of Oncology · doi:10.1016/s0923-7534(21)00599-8 · Cited by 41

Hypofractionated EGFR tyrosine kinase inhibitor limits tumor relapse through triggering innate and adaptive immunity

Liu, Z., Han, C., Dong, C., Shen, A., Hsu, E. J., Ren, Z., Lu, C., Liu, L., Zhang, A., Timmerman, C., et al. (2019) · Science Immunology · doi:10.1126/sciimmunol.aav6473 · Cited by 41

Patients With Short PFS to EGFR-TKIs Predicted Better Response to Subsequent Anti-PD-1/PD-L1 Based Immunotherapy in EGFR Common Mutation NSCLC

Liu, S., Wu, F., Li, X., Zhao, C., Jia, Y., Jia, K., Han, R., Qiao, M., Li, W., Yu, J., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.639947 · Cited by 36

Immune-Modulation by Epidermal Growth Factor Receptor Inhibitors: Implication on Anti-Tumor Immunity in Lung Cancer

Im, J. S., Herrmann, A. C., Bernatchez, C., Haymaker, C., Molldrem, J. J., Hong, W. K., & Perez-Soler, R. (2016) · PLoS ONE · doi:10.1371/journal.pone.0160004 · Cited by 35

Nivolumab in non-small-cell lung cancer with EGFR mutation

Yoshida, H., Kim, Y. H., Ozasa, H., Nagai, H., Sakamori, Y., Tsuji, T., Nomizo, T., Yasuda, Y., Funazo, T. Y., & Hirai, T. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx745 · Cited by 35

Vaccine immunotherapy in lung cancer: Clinical experience and future directions

Freeman-Keller, M., Goldman, J. M., & Gray, J. E. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.05.004 · Cited by 34

Circulating CD8+ T-cell repertoires reveal the biological characteristics of tumors and clinical responses to chemotherapy in breast cancer patients

Lin, K.-R., Pang, D., Jin, Y., Hu, Q., Pan, Y.-M., Cui, J., Chen, X., Lin, Y.-X., Mao, X., Duan, H., et al. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2213-1 · Cited by 34

Depression, inflammation, and epidermal growth factor receptor (EGFR) status in metastatic non-small cell lung cancer: A pilot study

Jacobs, J. M., Traeger, L. N., Eusebio, J. R., Simon, N. M., Sequist, L. V. D., Greer, J. A., Temel, J. S., & Pirl, W. F. (2017) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2017.05.009 · Cited by 30

Impact of EGFR-TKIs combined with PD-L1 antibody on the lung tissue of EGFR-driven tumor-bearing mice

Jia, Y., Zhao, S., Jiang, T., Li, X., Zhao, C., Liu, Y., Han, R., Qiao, M., Liu, S., Su, C., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.09.016 · Cited by 27

Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial

Thress, K. S., Jacobs, V. N., Angell, H. K., Yang, J. C., Sequist, L. V. D., Blackhall, F. H., Su, W., Schüler, M., Wolf, J., Gold, K. A., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.07.011 · Cited by 25

Association of CD8 T cell apoptosis and EGFR mutation in non‐small lung cancer patients

Zhao, C., Su, C., Li, X., & Zhou, C. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13504 · Cited by 23

The Superior Ability of Human BDCA3+ (CD141+) Dendritic Cells (DCs) to Cross-Present Antigens Derived From Necrotic Lung Cancer Cells

Gu, F., Zhang, K., Ma, L., Liu, Y., Li, C., Hu, Y., Yang, Q., Liang, J., Zeng, Y., Wang, Y., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01267 · Cited by 22

Immunologic and clinical implications of CD73 expression in non-small cell lung cancer (NSCLC).

Park, L. C., Rhee, K., Kim, W. B., Cho, A., Song, J., Anker, J. F., Oh, M. S., Bais, P., Namburi, S., Chuang, J. H., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.12050 · Cited by 20

Epidermal growth factor receptor inhibition by erlotinib prevents vascular smooth muscle cell and monocyte–macrophage function in vitro

Savikko, J., Rintala, J. M. J., Rintala, S. E., & Koskinen, P. (2015) · Transplant Immunology · doi:10.1016/j.trim.2015.03.001 · Cited by 18

1293P IMpower150: Updated efficacy analysis in patients with EGFR mutations

Reck, M., Mok, T. S. K., Socinski, M. A., Jotte, R. M., Lim, W., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez‐Abreu, D., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.1607 · Cited by 18

Effect of Combined Therapy Inhibiting EGFR and VEGFR Pathways in Non–Small-cell Lung Cancer on Progression-free and Overall Survival

Jiang, T., Qiao, M., Zhou, F., Ren, S., Su, C., & Zhou, C. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.12.012 · Cited by 17

Impact of gefitinib in early stage treatment on circulating cytokines and lymphocytes for patients with advanced non–small cell lung cancer

Jin, S., Fang, W., Liu, X., Xing, S., Zhan, J., Ma, Y., Huang, Y., Zhou, N., Zhao, H., & Zhang, L. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s112158 · Cited by 17

Prospects for a personalized peptide vaccine against lung cancer

Nakahara, Y., Kouro, T., Igarashi, Y., Kawahara, M., & Sasada, T. (2019) · Expert Review of Vaccines · doi:10.1080/14760584.2019.1635461 · Cited by 15

Multimarker scores of Th1 and Th2 immune cellular profiles in peripheral blood predict response and immune related toxicity with CTLA4 blockade and IFNα in melanoma

Khunger, A., Sarikonda, G., Tsau, J., Pahuja, A., Alfonso, Z., Gao, J., Laing, C., Vaupel, C., Dakappagari, N. K., & Tarhini, A. A. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101014 · Cited by 15

A multi-center phase II study of toripalimab with chemotherapy in patients with EGFR mutant advanced NSCLC patients resistant to EGFR TKIs: Efficacy and biomarker analysis.

Ren, S., Zhang, J., Zhao, Y., Mu, X., Zhou, J., Bao, Z., Fan, Y., Xu, Y., Shu, Y., Guo, R., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.e21618 · Cited by 14

Favorable Immune Microenvironment in Patients with EGFR and MAPK Co-Mutations

Yang, W., Chen, N., Li, L., Chen, X., Liu, X., Zhang, Y., & Cui, J. (2020) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s262822 · Cited by 13

Phase I study of gefitinib (G) + durvalumab (D) for locally advanced/metastatic non-small cell lung cancer (NSCLC) harbouring epidermal growth factor receptor (EGFR) sensitising mutations

Creelan, B., Yeh, T. C., Kim, S., Nogami, N., Kim, D.-W., Chow, L. Q. M., Kanda, S., Taylor, R., Tang, W., Tang, M., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz067.001 · Cited by 12

Acute-phase reaction induced by zoledronate and its effect on prognosis of patients with advanced non-small cell lung cancer

Izumi, H., Yamasaki, A., Takeda, K., Kodani, M., Touge, H., Tanaka, N., Yanai, M., Ueda, Y., Sakamoto, T., Nishii‐Ito, S., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.06.022 · Cited by 11

Tumor Microenvironment Properties are Associated With Low CD68-positive Cell Infiltration and Favorable Disease-free Survival in EGFR-mutant Lung Adenocarcinoma

Gong, Z., Chen, J., Cheng, J., Sun, C., Jia, Q., Diao, X., & Zhu, B. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.03.011 · Cited by 10

MA19.01 Efficacy and Genomic Correlates of Response to Anti-PD1/PD-L1 Blockade in Non-Small Cell Lung Cancers Harboring Targetable Oncogenes

Vokes, N. I., Alguilar, E. J., Adeni, A. E., Umeton, R., Sholl, L. M., Rizvi, H. A., Hellmann, M. D., Awad, M. M., & Allen, E. M. V. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.08.474 · Cited by 10

Long-term responders to PD-1 blockade in patients with advanced non-small cell lung cancer (NSCLC).

Luo, J., Bandlamudi, C., Ricciuti, B., Vokes, N. I., Schoenfeld, A. J., Egger, J. V., Sauter, J. L., Plodkowski, A. J., Preeshagul, I. R., Kris, M. G., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.9549 · Cited by 10

Predictive value of CD73 expression in EGFR-mutation positive non-small-cell lung cancer patients received immune checkpoint inhibitors.

Ishii, H., Azuma, K., Kinoshita, T., Matsuo, N., Naito, Y., Tokito, T., Yamada, K., & Hoshino, T. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.9065 · Cited by 8

Abstract 4981: PI3K/AKT/mTOR pathway activation drives expression of the immune inhibitory ligand PD-L1 in NSCLC.

Lastwika, K. J., Wilson, W., & Dennis, P. A. (2013) · Cancer Research · doi:10.1158/1538-7445.am2013-4981 · Cited by 7

Tumor Immune Microenvironment of EGFR -mutant Non-Small-Cell Lung Cancer and its Impact on Therapeutic Efficacy

Matsumoto, Y., & Koh, Y. (2020) · Immunotherapy · doi:10.2217/imt-2019-0213 · Cited by 6

Abstract 3181: EGFR and KRAS activation generate discrete inflammatory responses within the lung tumor microenvironment

Busch, S., Hanke, M. L., Kim, K. H., Kargl, J., & Houghton, A. M. (2015) · Cancer Research · doi:10.1158/1538-7445.am2015-3181 · Cited by 3

The tumor microenvironment in EGFR-driven loco-regional lung adenocarcinoma can predict higher risk of recurrence.

Khalil, M., Elkhanany, A. M., Yang, Y., Glenn, S. T., Papanicolau‐Sengos, A., Morrison, C., & Dy, G. K. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.8521 · Cited by 3

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions

Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445

Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade

Genova, C., Dellepiane, C., Carrega, P., Sommariva, S., Ferlazzo, G., Pronzato, P., Gangemi, R. M. R., Filaci, G., Coco, S., & Croce, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.799455 · Cited by 273

Current Landscape of Non-Small Cell Lung Cancer: Epidemiology, Histological Classification, Targeted Therapies, and Immunotherapy

Rodak, O., Peris‐Díaz, M. D., Olbromski, M., Podhorska‐Okołów, M., & Dzięgiel, P. (2021) · Cancers · doi:10.3390/cancers13184705 · Cited by 250

The changing treatment landscape of EGFR-mutant non-small-cell lung cancer

Zhou, F., Guo, H., Xia, Y., Le, X., Tan, D. S. W., Ramalingam, S. S., & Zhou, C. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00971-2 · Cited by 230

Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trial

Jiang, T., Wang, P., Zhang, J., Zhao, Y., Zhou, J., Fan, Y., Shu, Y., Liu, X., Zhang, H., He, J., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00751-9 · Cited by 95

Persist or resist: Immune checkpoint inhibitors in EGFR ‐mutated NSCLC

Zhu, P., Li, Z., Sun, Y., Liu, T., & Yin, R. H. (2024) · Cancer Science · doi:10.1111/cas.16428 · Cited by 10

It might be a dead end: immune checkpoint inhibitor therapy in EGFR-mutated NSCLC

Akao, K., Oya, Y., Sato, T., Ikeda, A., Horiguchi, T., Gotô, Y., Hashimoto, N., Kondo, M., & Imaizumi, K. (2024) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2024.00251 · Cited by 6

The efficacy and possible mechanisms of immune checkpoint inhibitors in treating non‐small cell lung cancer patients with epidermal growth factor receptor mutation

Ma, L., Diao, B., Huang, Z., Wang, B., Yu, J., & Meng, X. (2021) · 癌症：英文版 · doi:10.1002/cac2.12229 · Cited by 33

[Progress of Immunotherapy in EGFR-mutated Advanced Non-small Cell Lung Cancer].

Liu, Y., & Miao, J. (2024) · PubMed Central · doi:10.3779/j.issn.1009-3419.2023.106.26 · Cited by 2

Biomarker analyses to predict benefit of immune checkpoint inhibitors for EGFR-mutated non-small cell lung cancer

Azuma, K., Osuga, M., Itoh, S., Kawa, Y., Kozuki, T., Toi, Y., Murotani, K., Izumi, M., Murata, D., Hata, A., et al. (2026) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2026.101127